These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35675755)

  • 1. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
    Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
    Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferred Conformation-Guided Discovery of Potent and Orally Active HIF Prolyl Hydroxylase 2 Inhibitors for the Treatment of Anemia.
    Wu Y; Zhang L; Sun Z; Qiu X; Chen Y; Su K; Yang L; Du Z; Dong Y; Yang F; Li X; Zhang X
    J Med Chem; 2023 Jul; 66(13):8545-8563. PubMed ID: 37367818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
    Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
    Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
    Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
    Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
    Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
    J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel prolyl hydroxylase-2 inhibitor caffeic acid upregulates hypoxia inducible factor and protects against hypoxia.
    Guo Z; Yang Y; Li L; Zhao Q; Li Y; Liu Z; Hao L; Guo B; Diao A
    Eur J Pharmacol; 2022 Nov; 934():175307. PubMed ID: 36191632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation.
    Kato S; Takayama N; Takano H; Koretsune H; Koizumi C; Kunioka EI; Uchida S; Takahashi T; Yamamoto K
    Eur J Pharmacol; 2018 Nov; 838():138-144. PubMed ID: 30179610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
    Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
    Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
    Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factor prolyl-hydroxylase 2 senses high-salt intake to increase hypoxia inducible factor 1alpha levels in the renal medulla.
    Wang Z; Zhu Q; Xia M; Li PL; Hinton SJ; Li N
    Hypertension; 2010 May; 55(5):1129-36. PubMed ID: 20308610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
    Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
    J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.
    Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X
    Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells.
    Han WQ; Zhu Q; Hu J; Li PL; Zhang F; Li N
    Biochim Biophys Acta; 2013 Jun; 1833(6):1454-62. PubMed ID: 23466866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial prolyl hydroxylase 2 is necessary for angiotensin II-mediated renal fibrosis and injury.
    Zhao Y; Zeng H; Liu B; He X; Chen JX
    Am J Physiol Renal Physiol; 2020 Aug; 319(2):F345-F357. PubMed ID: 32715763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.
    Li Z; Su K; Jiang Z; Yu Y; You Q; Zhang X
    J Med Chem; 2019 Aug; 62(16):7583-7588. PubMed ID: 31244107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.